Edwards Tweaks 2025 Outlook Amid Strong Q2 Heart Therapy Performance

Edwards tweaks 2025 outlook amid strong Q2 heart therapy performance

Edwards Lifesciences has lifted its 2025 profit outlook to between 9%-10%, up from 8%-10%, amid strong Q2 2025 performance in its Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT) business segments.The post Edwards tweaks 2025 outlook amid strong Q2 heart therapy performance appeared first on Medical Device Network.

Edwards Rises 6.3% on Q2 Results - Orange County Business Journal

Shares in Edwards Lifesciences Corp. rose 6.3% in after-hours trading after posting second quarter earnings that beat analysts’ expectations. The medical device maker reported that second-quarter revenue grew 12% to $1.53 billion, surpassing estimates of $1.49 billion. Edwards also reported adjusted earnings per share of 67 cents, above the 62 cents expected by analysts. “We are pleased to report strong second quarter results that delivered doub…